Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
143 studies found for:    Efavirenz / Emtricitabine / Tenofovir disoproxil fumarate OR Atripla[TREATMENT] AND HIV [CONDITION]
Show Display Options
Rank Status Study
1 Recruiting Sleep and Cognition After Atripla to Stribild Switch
Condition: HIV
Interventions: Drug: Stribild;   Drug: Atripla
2 Completed
Has Results
Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: Stribild;   Drug: Atripla;   Drug: Stribild Placebo;   Drug: Atripla Placebo
3 Completed
Has Results
Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: Stribild;   Drug: Atripla
4 Active, not recruiting Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults
Condition: HIV-1 Infection
Interventions: Drug: FTC/RPV/TAF;   Drug: EFV/FTC/TDF Placebo;   Drug: EFV/FTC/TDF;   Drug: FTC/RPV/TAF Placebo
5 Active, not recruiting Comparison of MK-1439A and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus (HIV)-Infected Participants (MK-1439A-021)
Condition: Human Immunodeficiency Virus (HIV)
Interventions: Drug: MK-1439A;   Drug: ATRIPLA™
6 Completed ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla
Condition: HIV Infections
Intervention: Drug: Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg
7 Completed
Has Results
Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Condition: HIV-1 Infection
Interventions: Drug: FTC/RPV/TDF;   Drug: EFV/FTC/TDF
8 Completed Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine
Condition: HIV
Intervention: Drug: ATRIPLA
9 Completed
Has Results
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
Condition: Infection, Human Immunodeficiency Virus I
Interventions: Drug: Dolutegravir;   Drug: Atripla;   Drug: Abacavir/Lamivudine;   Drug: Abacavir/Lamivudine Placebo;   Drug: Dolutegravir placebo;   Drug: Atripla placebo
10 Completed
Has Results
Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR
Condition: HIV-1 Infection
Intervention: Drug: FTC/RPV/TDF
11 Recruiting Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning
Conditions: Neurocognitive Decline;   HIV Associated Neurocognitive Disorder
Intervention: Drug: Eviplera
12 Completed Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients
Condition: Tuberculosis
Interventions: Drug: rifapentine (M000473);   Drug: EFZ EMT TDF
13 Active, not recruiting Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla
Condition: HIV-1
Interventions: Drug: efavirenz + emtricitabina + tenofovir;   Drug: rilpivirina + emtricitabina + tenofovir
14 Completed Atripla to Stribild Switch Study to Evaluate Sleep Disturbances
Conditions: HIV;   AIDS;   Sleep Disorders
Intervention: Drug: elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil
15 Active, not recruiting SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms
Condition: HIV
Intervention: Drug: Eviplera
16 Recruiting Decrease of Neuropsychiatric Side Effects After Switching From Atripla to Eviplera
Condition: HIV
Interventions: Drug: Tenofovir disoproxil/emtricitabine/rilpivirine;   Drug: Tenofovir disoproxil/emtricitabine/efavirenz
17 Completed Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients
Condition: HIV Infections
Interventions: Drug: Kaletra + Isentress;   Drug: Atripla
18 Recruiting Effects of Switching From ATRIPLA^TM (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)
Conditions: HIV-1 Infection;   CNS Toxicity
Interventions: Drug: MK-1439A - Blinded;   Drug: MK-1439A - Open-Label;   Drug: ATRIPLA^TM;   Drug: Placebo to ATRIPLA^TM;   Drug: Placebo to MK-1439A
19 Completed
Has Results
Atripla to Raltegravir Switch Study for CNS Toxicity
Condition: HIV Infection
Intervention: Drug: Truvada/Raltegravir
20 Completed
Has Results
The Bioequivalence of Atripla in an Oral Liquid Formulation Compared With the Tablet Formulation in Healthy Volunteers
Condition: Healthy
Interventions: Drug: tenofovir, emtricitabine and efavirenz fixed dose tablet;   Drug: tenofovir, emtricitabine and efavirenz tablet added to solution

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.